摘要
胃癌发生隐匿,恶性程度较高,对传统放化疗不敏感,预后差,因此,研发新型抗胃癌药物迫在眉睫。抗体偶联药物(Antibody-drug conjugate,ADC)是由单克隆抗体经特定的连接子与细胞毒药物连接而成的一类靶向生物制剂,具有高效、靶向、精准、低毒等优势。目前,ADC已广泛用于治疗血液系统肿瘤及实体肿瘤,并在晚期胃癌的治疗中展现出良好疗效,具有广阔的应用前景。
The occurrence of gastric cancer is occult with high degree of malignancy,it is not sensitive to the traditional radiotherapy and chemotherapy,and the prognosis is poor.Therefore,it is urgent to develop new drugs to treat gastric cancer.Antibody-drug conjugate(ADC)is a class of targeted biologics formed by linking monoclonal antibodies with cytotoxic drugs via specific linkers.It has the advantages of high efficiency,targeting,precision and low toxicity.At present,ADC has been widely used in the treatment of hematological and solid tumors,and has shown good efficacy in the treatment of advanced gastric cancer with broad application prospects.
作者
吴雨微
阎金杉
赵明芳
Wu Yuwei;Yan Jinshan;Zhao Mingfang(Institute of Biological Therapy,the First Hospital of China Medical University,Shenyang 110001,China;Second Ward of Oncology Department,the First Hospital of China Medical University,Shenyang 110001,China)
出处
《实用药物与临床》
CAS
2024年第6期449-456,共8页
Practical Pharmacy and Clinical Remedies
基金
国家自然科学基金(82373413)
辽宁省中央引导地方科技发展资金第二批计划项目(2022010127-JH6/1001)。
关键词
抗体偶联药物
胃癌
靶向治疗
Antibody-drug conjugate(ADC)
Gastric cancer
Targeted therapy
